Literature DB >> 19433249

The pancreatic beta-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes.

Angel Nadal1, Paloma Alonso-Magdalena, Sergi Soriano, Ivan Quesada, Ana B Ropero.   

Abstract

The estrogen receptor ERalpha is emerging as a key molecule involved in glucose and lipid metabolism. The main functions of pancreatic beta-cells are the biosynthesis and release of insulin, the only hormone that can directly decrease blood glucose levels. Estrogen receptors ERalpha and ERbeta exist in beta-cells. The role of ERbeta is still unknown, yet ERalpha plays an important role in the regulation of insulin biosynthesis, insulin secretion and beta-cell survival. Activation of ERalpha by 17beta-estradiol (E2) and the environmental estrogen bisphenol-A (BPA) promotes an increase of insulin biosynthesis through a non-classical estrogen-activated pathway that involves phosphorylation of ERK1/2. The activation of ERalpha by physiological concentrations of E2 may play an important role in the adaptation of the endocrine pancreas to pregnancy. However, if ERalpha is over stimulated by an excess of E2 or the action of an environmental estrogen such as BPA, it will produce an excessive insulin signaling. This may provoke insulin resistance in the liver and muscle, as well as beta-cell exhaustion and therefore, it may contribute to the development of type II diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19433249     DOI: 10.1016/j.mce.2009.02.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  82 in total

1.  Maternal urinary phthalate metabolites in relation to gestational diabetes and glucose intolerance during pregnancy.

Authors:  Rachel M Shaffer; Kelly K Ferguson; Lianne Sheppard; Tamarra James-Todd; Samantha Butts; Suchitra Chandrasekaran; Shanna H Swan; Emily S Barrett; Ruby Nguyen; Nicole Bush; Thomas F McElrath; Sheela Sathyanarayana
Journal:  Environ Int       Date:  2019-01-07       Impact factor: 9.621

Review 2.  Nongenomic signaling pathways of estrogen toxicity.

Authors:  Cheryl S Watson; Yow-Jiun Jeng; Mikhail Y Kochukov
Journal:  Toxicol Sci       Date:  2009-12-02       Impact factor: 4.849

Review 3.  Endocrine disruptors in the etiology of type 2 diabetes mellitus.

Authors:  Paloma Alonso-Magdalena; Ivan Quesada; Angel Nadal
Journal:  Nat Rev Endocrinol       Date:  2011-04-05       Impact factor: 43.330

4.  Getting big on BPA: role for BPA in obesity?

Authors:  Alan Schneyer
Journal:  Endocrinology       Date:  2011-09       Impact factor: 4.736

Review 5.  Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome.

Authors:  Andrea L Hevener; Deborah J Clegg; Franck Mauvais-Jarvis
Journal:  Mol Cell Endocrinol       Date:  2015-05-29       Impact factor: 4.102

Review 6.  Emerging roles of GPER in diabetes and atherosclerosis.

Authors:  Matthias Barton; Eric R Prossnitz
Journal:  Trends Endocrinol Metab       Date:  2015-03-09       Impact factor: 12.015

Review 7.  Polluted Pathways: Mechanisms of Metabolic Disruption by Endocrine Disrupting Chemicals.

Authors:  Mizuho S Mimoto; Angel Nadal; Robert M Sargis
Journal:  Curr Environ Health Rep       Date:  2017-06

8.  Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring.

Authors:  Paloma Alonso-Magdalena; Elaine Vieira; Sergi Soriano; Lorena Menes; Deborah Burks; Ivan Quesada; Angel Nadal
Journal:  Environ Health Perspect       Date:  2010-05-07       Impact factor: 9.031

9.  Combinations of physiologic estrogens with xenoestrogens alter calcium and kinase responses, prolactin release, and membrane estrogen receptor trafficking in rat pituitary cells.

Authors:  Yow-Jiun Jeng; Mikhail Kochukov; Cheryl S Watson
Journal:  Environ Health       Date:  2010-10-15       Impact factor: 5.984

10.  Effects of estrogen on hyperglycemia and liver dysfunction in diabetic male rats.

Authors:  Marwa A Ahmed; Khaled M A Hassanein
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.